NCT03718468View on ClinicalTrials.gov

A Study to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

842

Participants

Timeline

Start Date

October 30, 2018

Primary Completion Date

July 3, 2019

Study Completion Date

July 3, 2019

Conditions
Influenza
Interventions
BIOLOGICAL

GC FLU Quadrivalent

A single dose administration of GC FLU Quadrivalent will be through intramuscular injection.

BIOLOGICAL

Fluarix Tetra

A single dose administration of Fluarix Tetra will be through intramuscular injection.

Trial Locations (4)

Unknown

National Taiwan University Hospital, Taipei

Taipei Municipal Wan Fang Hospital, Taipei

Tri-Service General Hospital, Taipei

Linkou Chang Gung Memorial Hospital, Taoyuan District

Sponsors
All Listed Sponsors
lead

Medigen Vaccine Biologics Corp.

INDUSTRY

NCT03718468 - A Study to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine | Biotech Hunter | Biotech Hunter